Researchers discovered a new epigenetic therapy that remained effective in treatment-resistant acute myeloid leukemia (AML) through activating the Hippo pathway, a tumor-suppressing pathway linked to cancer growth and drug resistance. The therapy, NTX-301, consistently reduced leukemia cell survival more effectively than existing hypom...
Using the YEARS diagnostic algorithm is as safe as computed tomographic pulmonary angiography (CTPA) for diagnosing suspected pulmonary embolism in patients with cancer. This strategy saved 22% of patients from undergoing CTPA, highlighting its potential to streamline cancer care.
Recent studies have challenged the classical view of immune checkpoints as local suppressive molecules only active in tumor immunity. Instead, ICs participate in systemic immune homeostasis and are embedded in broader inflammatory and metabolic networks.
Researchers have successfully mapped the cells and genes that regulate bone formation and loss, revealing blood vessel cells play a critical role in bone health. The discovery has the potential to enable the development of new therapies to reverse bone loss and improve treatments for osteoporosis and other skeletal conditions.
Deep learning models accelerate drug design, predict chemical interactions, and engineer stable candidates. AI-powered simulations optimize dosimetry, predicting biodistribution and generating patient-specific digital twins for individualized treatment planning.
A new study found that prophylactic naldemedine is a cost-effective intervention for opioid-induced constipation in cancer patients. The analysis revealed an incremental cost-effectiveness ratio of 1,445,276 Japanese yen per QALY gained, which is below the official willingness-to-pay threshold of 5 million yen.
A new preclinical study has identified a gut bacterium, Akkermansia muciniphila, that helps prime intestinal stem cells for faster recovery after radiation treatment. Fasting increases the population of this bacterium, which produces a small molecule that changes histone tags to allow gene expression in intestinal cells.
A new study found that over 50 million Americans live in counties without a radiation oncology clinic, highlighting vulnerabilities in the nation's cancer care infrastructure. Radiation oncology practices have closed disproportionately in rural areas and freestanding settings, raising concerns about patients' access to cancer care.
Researchers found that yeast-based supplements can reprogram early-stage immune cells to produce enhanced anti-tumor responses. The study suggests a potential solution for obesity-related immune dysfunction and cancer, using a food-grade supplement with an excellent safety record.
A new study reports that forty percent of women with ovarian cancer only receive a diagnosis after an emergency hospital admission. Women diagnosed through this route are four times more likely to die within two months of diagnosis.
A global analysis found alcohol use and smoking to be common risk factors for both breast cancer and atrial fibrillation/flutter in women ages 55 and older. High-risk zones were predominantly in Western countries with greater exposure to these lifestyle risks.
A recent report from the American Cancer Society reveals an urgent picture of a growing global cancer burden. Nearly 21 million people were diagnosed with cancer and 9.8 million died from the disease globally in 2024, with the number of cases projected to reach 34 million by 2050.
Breast cancers diagnosed during the first three years after childbirth are biologically more aggressive than similar cancers in women who have never given birth. The Oncotype DX Breast Recurrence Score suggests biological features associated with a higher risk of recurrence among these patients, including higher-grade tumors.
Researchers identified why some patients with rare blastic plasmacytoid dendritic cell neoplasm (BPDCN) leukemia don't respond to tagraxofusp. Severe TET2 gene mutations and low TXNRD1 enzyme levels contribute to resistance, suggesting these biomarkers could predict treatment outcomes.
Physicists at UTEP have discovered a new type of manganese ferrite nanoparticle that can deliver targeted heat treatment to tumors, potentially improving cancer therapies. The nanoparticles were found to produce a stronger heating response than other materials, making them a promising building block for future treatments.
Recent studies have expanded our understanding of immune checkpoint functions, revealing their involvement in systemic immune homeostasis and broader inflammatory networks. Aberrant IC regulation has been linked to various conditions, including infections, autoimmune diseases, and metabolic inflammation.
Researchers at the University of Texas M. D. Anderson Cancer Center found that inotuzumab ozogamicin effectively clears measurable residual disease in B-cell acute lymphoblastic leukemia patients, leading to improved long-term survival outcomes and durable responses.
A non-invasive brush biopsy test has been validated for accurate oral cancer detection within one hour, potentially sparing over 90% of low-risk patients from unnecessary invasive procedures. The test's performance is comparable to a microbiopsy-based assay, making it a game-changer in oral cancer diagnosis and treatment.
The study reveals that the protein ASPA acts as a natural brake on cancer-associated fibroblasts, which play a critical role in tumour growth and metastasis. ASPA's loss is associated with more aggressive disease progression across different types of cancer.
A new study has identified molecular tumor characteristics that distinguish between different subtypes of diffuse large B-cell lymphoma (DLBCL). The findings suggest that tumors from high-risk patients, referred to as PG4 proteogenotype, are characterized by specific genetic mutations and protein patterns. These characteristics can hel...
A Phase I/II study showed high tumor shrinkage and substantial reductions in cancer DNA detected in the bloodstream. The treatment combination of zoldonrasib with chemotherapy improved patient outcomes, suggesting a potential breakthrough in personalized treatment for pancreatic cancer.
A new study by Thales Papagiannakopoulos and colleagues found that lung cancer tumors talk directly to the nervous system through sensory neurons in the lungs, promoting cachexia. Silencing these nerves or blocking the production of prostaglandin E2 (PGE2) reduced cachexia, suggesting a potential therapeutic strategy.
A blood test may help identify which patients with colorectal cancer that has spread to the liver are most likely to benefit from chemotherapy after surgery. Patients with detectable circulating tumour DNA (ctDNA) who received adjuvant chemotherapy had markedly better outcomes, including a 93% reduction in recurrence.
The study identified two proteins, BCL2 and MCL1, as predictive biomarkers for matching patients to specific drug combinations. Combining BRAF-MEK inhibitors with a BCL2 inhibitor induced tumor regression in previously resistant tumors.
Researchers identified a new pathway linking lung tumor genetics, diet, and the nervous system that drives cancer-associated cachexia. A high-fat diet exacerbated the condition by reducing appetite and physical activity, while blocking prostaglandin E2 synthesis restored appetite and improved survival.
Researchers paired CAR T cell immunotherapy with a targeted radiopharmaceutical to improve tumor regression in preclinical models of neuroblastoma. The combination therapy worked through different mechanisms depending on the tumor's sensitivity to radiation.
Researchers at McMaster University have developed a cancer immunotherapy strategy targeting glioblastoma, one of the most aggressive brain tumours. The therapy, using Chimeric Antigen Receptor T-cell therapy, recognizes and attacks both the tumour cells and immune cells that support their growth, offering a new approach to treatment.
A new portable ultrasound system enhances breast cancer detection with high-resolution, 3D images. The device requires no expertise to operate and can be used at home for early diagnosis and long-term monitoring.
A new imaging technology at UH helps scientists study exosomes, tiny particles released by human cells that may be targets for diseases. The technology uses advanced lighting at the nanoscale to analyze exosomes one at a time, measuring features to pinpoint good drug targets.
Researchers developed a strategy to attack glioblastoma on two fronts by targeting the tumour and its immune support system. In preclinical models, the therapy eliminated detectable tumours and led to long-term disease-free survival.
Researchers found that long noncoding RNAs can become integrated into ancient cellular pathways regulating cancer, providing fresh insights into disease and potential therapeutic targets. The study identified a specific lncRNA, MIR497HG, as a key player in this process.
A new study published in Nature links casdatifan, an investigational HIF-2a inhibitor, to improved clinical outcomes in metastatic clear cell renal cell carcinoma (ccRCC) patients. Deep suppression of serum EPO correlated with higher response rates and longer progression-free survival.
Jill Mesirov brings expertise in computational biology and genomics to Sanford Burnham Prebys, aiming to advance cancer research and treatment. She will mentor next-gen computational biologists and leverage AI tools to personalize therapy.
Researchers estimate that relabeling Grade Group 1 prostate cancer as a precancerous condition could reduce unnecessary treatment and prevent nearly 2,400 prostate cancer deaths annually. This change may encourage more men to get screened, potentially leading to fewer deaths from aggressive prostate cancer.
The Ludwig Institute for Cancer Research has appointed three Clinical Scholars, Bernhard Gentner, Caroline Arber, and Christian Hinrichs, to advance cancer research and clinical interventions. The new scholars will focus on translating scientific discoveries into clinical trials and partnerships with leading clinical facilities.
A new AI model, SpliceSelectNet, accurately predicts RNA splicing by capturing long-range DNA signals. The model's hierarchical Transformer architecture preserves high computational efficiency while maintaining single-nucleotide resolution, enabling accurate analysis of genomic regions.
A genomic study found two previously unreported truncating germline variants in BRCA2, suggesting inherited alterations may contribute to susceptibility to multiple primary lung cancers. The study also points toward important clinical applications, including the use of PARP inhibitors and molecularly targeted approaches for treatment.
Researchers at the University of Turku have developed a reliable laboratory model to study BAP1-deficient melanomas, which are resistant to immunotherapies. The new tool could lead to novel immunotherapy combinations for aggressive melanomas.
A CU Anschutz study reveals reduced mitochondrial efficiency in healthy yet sedentary individuals, which may precede the development of major diseases like cancer, diabetes, and Alzheimer's. Regular exercise acts as a literal shield for cellular health, helping mitochondria seamlessly switch between burning fat and carbohydrates.
Recent research suggests that senescence often limits stem cell activity in normal tissues but can also promote tumor progression in cancer. Understanding the dynamic interplay between these two biological processes is crucial for developing safer regenerative therapies and more effective cancer treatments.
Researchers developed an AI framework to identify viable target antigens for CAR T cell therapy, using publicly available single-cell RNA sequencing data. The framework showed robust tumor-killing activity in mouse models of multiple cancer types, including melanoma, leukemia, and colorectal cancer.
Researchers have uncovered a potential strategy to eliminate cancer cells that survive KRAS inhibition, preventing relapse. By targeting the metabolic pathways that support the survival of drug-tolerant persister cells, treatment regimens could be designed to shrink tumors and prevent cancer recurrence.
Researchers at Texas A&M University develop a laser technique called TRIP to directly measure quantum forces shaping proteins, enabling accurate prediction of how pharmaceutical drugs interact with them. This breakthrough could lead to the design of medicines tailored to specific diseases, revolutionizing precision medicine.
Researchers identified miR-29a as a pivotal regulator of cancer development, which can act as both a tumor suppressor and an oncogene. Natural bioactive compounds such as curcumin, EGCG, and resveratrol have been shown to restore normal miR-29a expression through epigenetic remodeling and inhibition of oncogenic signaling pathways.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center receive $1.7M grant to advance CAR T-cell therapies for metastatic castration-resistant prostate cancer. They will investigate a new approach combining engineered nanovial technology with single-cell analysis to rapidly evaluate and optimize dual-targeted CAR T-cell therapies.
Researchers discover a novel mechanism where PVT1 and EIF4A1 drive gastric cancer metastasis through the Notch-1 signaling pathway, resulting in increased tumour cell migration, invasion, and proliferation. Elevated STC1 levels confirm its role as a key downstream effector of this axis.
A phase III trial is investigating whether an immune-boosting drug can help keep early-stage lung cancer from coming back after surgery. Researchers aim to enroll 336 participants with stage I non-small cell lung cancer and determine if the treatment reduces recurrence.
Combined hepatocellular-cholangiocarcinoma is a rare and aggressive form of primary liver cancer that poses significant diagnostic and therapeutic challenges. The absence of standardized treatment guidelines limits effective management, emphasizing the need for thorough pathological evaluation and multidisciplinary management.
Researchers found frequent silencing of TRAIL-R2 in breast tumors through promoter hypermethylation, associated with invasive ductal carcinoma and advanced tumor stage. Lower TRAIL-R2 expression was linked to more aggressive disease and reduced overall survival.
Researchers discover microbes can induce immunogenic cell death, activating immune system against tumors. This process transforms immunologically 'cold,' therapy-resistant tumors into 'hot,' responsive ones by triggering damage-associated molecular patterns (DAMPs).
A new blood test, Stockholm3, detected significantly more aggressive prostate cancers than the PSA test without increasing unnecessary follow-ups. The study shows that Stockholm3 identifies 90% of aggressive cancer cases, compared to 74% for PSA.
A new study from Kaiser Permanente found that combining AI mammographic risk scores with polygenic and clinical risk scores more accurately identifies women at high risk of developing breast cancer than clinical risk scores used alone. The combined model was found to improve prediction accuracy, particularly among women at highest risk.
The collaboration aims to eliminate barriers to screening and access for medically underserved women, leveraging data science and community-based research to develop targeted solutions. By listening to residents' experiences and challenges, USC and Novartis will create lasting improvements in breast cancer care.
Researchers seek to understand the biological mechanisms behind Ewing sarcoma's rapid growth and spread, developing new tools to visualize DNA structures and regulate gene expression. This could lead to personalized cancer treatments targeting specific molecules for improved patient outcomes.
Researchers have developed a versatile uncertainty-aware AI framework called TRUECAM that provides customizable accuracy guarantees for cancer subtype classifications. TRUECAM outperforms existing approaches to digital pathology AI uncertainty quantification, detecting out-of-scope inputs and improving fairness across sex and race.
Access to fertility preservation (FP) care is restricted among female adolescents and young adults with cancer due to costly and invasive interventions. The review highlights disparities in FP delivery and access based on age, socioeconomic status, and cancer type.
Researchers developed a method combining AI and mathematical models to accelerate MRI scans for breast cancer imaging, achieving improved tumor visibility and high diagnostic sensitivity. The ELITE method has the potential to improve not only MRI scans but also other imaging platforms.
Researchers developed RNovA algorithm to identify new PTMs in human cells, expanding capabilities of machine learning in basic biological research. The discovery aims to advance diagnostics and broaden biologists' horizons for cancer and other diseases.
The article explores ways clinicians can deliver care tailored to each patient's unique needs, priorities, and identities. Research highlights the importance of considering life transitions in supporting adolescents and young adults with cancer.
Researchers developed an AI-powered platform to track drug responses across thousands of patient-derived organoids, enabling real-time monitoring and analysis of tumor heterogeneity. The platform successfully measured how tumor organoids responded to drug treatment, providing a detailed view of treatment responses at the level of indiv...